Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)

    Summary
    EudraCT number
    2015-002024-89
    Trial protocol
    ES   DE   FI   SE   IE   DK   NL   FR   IT   BE  
    Global end of trial date
    17 Jul 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    13 Jul 2024
    First version publication date
    13 Jul 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    3475-177
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT02563002
    WHO universal trial number (UTN)
    -
    Other trial identifiers
    Merck: KEYNOTE-177
    Sponsors
    Sponsor organisation name
    Merck Sharp & Dohme LLC
    Sponsor organisation address
    126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ, United States, 07065
    Public contact
    Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@merck.com
    Scientific contact
    Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@merck.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    17 Jul 2023
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    19 Feb 2021
    Global end of trial reached?
    Yes
    Global end of trial date
    17 Jul 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    In this study, participants with stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) colorectal carcinoma (CRC) will be randomly assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for the treatment of advanced colorectal carcinoma. The primary study hypothesis is that pembrolizumab will prolong progression-free survival (PFS) or overall survival (OS) compared to current SOC chemotherapy.
    Protection of trial subjects
    This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    30 Nov 2015
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 20
    Country: Number of subjects enrolled
    United States: 55
    Country: Number of subjects enrolled
    Australia: 13
    Country: Number of subjects enrolled
    Belgium: 4
    Country: Number of subjects enrolled
    Brazil: 12
    Country: Number of subjects enrolled
    Canada: 6
    Country: Number of subjects enrolled
    Denmark: 22
    Country: Number of subjects enrolled
    Finland: 5
    Country: Number of subjects enrolled
    France: 36
    Country: Number of subjects enrolled
    Germany: 6
    Country: Number of subjects enrolled
    Ireland: 4
    Country: Number of subjects enrolled
    Israel: 8
    Country: Number of subjects enrolled
    Italy: 2
    Country: Number of subjects enrolled
    Japan: 22
    Country: Number of subjects enrolled
    Korea, Republic of: 14
    Country: Number of subjects enrolled
    Netherlands: 14
    Country: Number of subjects enrolled
    Norway: 9
    Country: Number of subjects enrolled
    Singapore: 5
    Country: Number of subjects enrolled
    South Africa: 4
    Country: Number of subjects enrolled
    Spain: 29
    Country: Number of subjects enrolled
    Sweden: 4
    Country: Number of subjects enrolled
    Switzerland: 6
    Country: Number of subjects enrolled
    Taiwan: 7
    Worldwide total number of subjects
    307
    EEA total number of subjects
    135
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    163
    From 65 to 84 years
    129
    85 years and over
    15

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    Of the 307 participants randomized in the study, 296 participants received study medication and were evaluable for safety analyses.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Pembrolizumab
    Arm description
    Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years). Eligible participants who stopped the initial course of pembrolizumab due to complete response (CR) or completed initial course of pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator’s discretion for up to 17 cycles (approximately 1 year additional).
    Arm type
    Experimental

    Investigational medicinal product name
    Pembrolizumab
    Investigational medicinal product code
    Other name
    MK-3475 SCH 90047 5KEYTRUDA®
    Pharmaceutical forms
    Powder for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years).

    Arm title
    Standard of Care (SOC)
    Arm description
    Participants received 1 of 6 possible standard chemotherapy regimens: mFOLFOX6, or mFOLFOX6+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or mFOLFOX6+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle, or FOLFIRI, or FOLFIRI+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or FOLFIRI+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle. Participants with documented disease progression following chemotherapy can crossover to receive pembrolizumab for up to 35 cycles (approximately 2 years). Eligible cross over participants who stopped pembrolizumab who stopped pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator’s discretion for up to 17 cycles (approximately 1 year additional).
    Arm type
    Active comparator

    Investigational medicinal product name
    mFOLFOX6
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Regimen consists of oxaliplatin 85 mg/m^2 IV on Day 1, leucovorin 400 mg/m^2 or levoleucovorin 200 mg/m^2 IV on Day 1, 5-fluorouracil (5-FU) 400 mg/m^2 IV bolus on Day 1 and then 1200 mg/m^2/day IV over 2 days for total dose of 2400 mg/m^2 in each 2-week cycle.

    Investigational medicinal product name
    Cetuximab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Cetuximab 400 mg/ m^2 IV over 2 hours first infusion, then 250mg/m^2 IV over 1 hour weekly.

    Investigational medicinal product name
    Bevacizumab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Bevacizumab 5 mg/kg IV on Day 1, every 2 weeks

    Investigational medicinal product name
    FOLFIRI
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Regimen consists of oxaliplatin 85 mg/m^2 IV on Day 1, leucovorin 400 mg/m^2 or levoleucovorin 200 mg/m^2 IV on Day 1, 5-fluorouracil (5-FU) 400 mg/m^2 IV bolus on Day 1 and then 1200 mg/m^2/day IV over 2 days for total dose of 2400 mg/m^2 in each 2-week cycle.

    Number of subjects in period 1
    Pembrolizumab Standard of Care (SOC)
    Started
    153
    154
    Treated
    153
    143
    Received Second Course of Pembrolizumab
    12
    5
    Switched over to Pembrolizumab
    0
    7
    Completed
    0
    0
    Not completed
    153
    154
         Adverse event, serious fatal
    72
    87
         Consent withdrawn by subject
    2
    10
         Physician decision
    -
    2
         Lost to follow-up
    5
    -
         Sponsor decision
    74
    55

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Pembrolizumab
    Reporting group description
    Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years). Eligible participants who stopped the initial course of pembrolizumab due to complete response (CR) or completed initial course of pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator’s discretion for up to 17 cycles (approximately 1 year additional).

    Reporting group title
    Standard of Care (SOC)
    Reporting group description
    Participants received 1 of 6 possible standard chemotherapy regimens: mFOLFOX6, or mFOLFOX6+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or mFOLFOX6+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle, or FOLFIRI, or FOLFIRI+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or FOLFIRI+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle. Participants with documented disease progression following chemotherapy can crossover to receive pembrolizumab for up to 35 cycles (approximately 2 years). Eligible cross over participants who stopped pembrolizumab who stopped pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator’s discretion for up to 17 cycles (approximately 1 year additional).

    Reporting group values
    Pembrolizumab Standard of Care (SOC) Total
    Number of subjects
    153 154 307
    Age categorical
    Units: Subjects
        In utero
        Preterm newborn infants (gestational age < 37 wks)
        Newborns (0-27 days)
        Infants and toddlers (28 days-23 months)
        Children (2-11 years)
        Adolescents (12-17 years)
        Adults (18-64 years)
        From 65-84 years
        85 years and over
    Age Continuous
    Units: Years
        arithmetic mean (standard deviation)
    61.9 ( 14.9 ) 60.6 ( 14.8 ) -
    Sex: Female, Male
    Units: Participants
        Female
    82 72 154
        Male
    71 82 153
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    0 0 0
        Asian
    24 26 50
        Native Hawaiian or Other Pacific Islander
    0 0 0
        Black or African American
    9 5 14
        White
    113 116 229
        More than one race
    0 0 0
        Unknown or Not Reported
    7 7 14
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    11 10 21
        Not Hispanic or Latino
    128 131 259
        Unknown or Not Reported
    14 13 27

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Pembrolizumab
    Reporting group description
    Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years). Eligible participants who stopped the initial course of pembrolizumab due to complete response (CR) or completed initial course of pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator’s discretion for up to 17 cycles (approximately 1 year additional).

    Reporting group title
    Standard of Care (SOC)
    Reporting group description
    Participants received 1 of 6 possible standard chemotherapy regimens: mFOLFOX6, or mFOLFOX6+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or mFOLFOX6+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle, or FOLFIRI, or FOLFIRI+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or FOLFIRI+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle. Participants with documented disease progression following chemotherapy can crossover to receive pembrolizumab for up to 35 cycles (approximately 2 years). Eligible cross over participants who stopped pembrolizumab who stopped pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator’s discretion for up to 17 cycles (approximately 1 year additional).

    Primary: Progression-Free Survival (PFS) per RECIST1.1 As Assessed by Central Imaging Vendor

    Close Top of page
    End point title
    Progression-Free Survival (PFS) per RECIST1.1 As Assessed by Central Imaging Vendor
    End point description
    PFS was defined as the time from randomization to the first documented disease progression (PD) per RECIST 1.1 based on blinded central imaging vendor review or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Hazards ratio (HR) and associated 95% confidence intervals (CIs) from a Cox proportional hazard model with Efron's method of tie handling and with a single treatment covariate was presented for the first course study treatment per protocol. The analysis population included all randomized participants.
    End point type
    Primary
    End point timeframe
    Up to approximately 59 months
    End point values
    Pembrolizumab Standard of Care (SOC)
    Number of subjects analysed
    153
    154
    Units: Months
        median (confidence interval 95%)
    16.5 (5.4 to 38.1)
    8.2 (6.1 to 10.2)
    Statistical analysis title
    Hazard Ratio
    Comparison groups
    Pembrolizumab v Standard of Care (SOC)
    Number of subjects included in analysis
    307
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.0001
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.59
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.45
         upper limit
    0.79

    Primary: Overall Survival (OS)

    Close Top of page
    End point title
    Overall Survival (OS)
    End point description
    OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of analysis were censored at the date of last known contact. HR and associated 95% CIs from a Cox proportional hazard model with Efron's method of tie handling and with a single treatment covariate was presented for the first course study treatment per protocol. The analysis population included all randomized participants.
    End point type
    Primary
    End point timeframe
    Up to approximately 59 months
    End point values
    Pembrolizumab Standard of Care (SOC)
    Number of subjects analysed
    153
    154
    Units: Months
        median (confidence interval 95%)
    9999 (49.2 to 9999)
    36.7 (27.6 to 9999)
    Statistical analysis title
    Hazards Ratio
    Comparison groups
    Pembrolizumab v Standard of Care (SOC)
    Number of subjects included in analysis
    307
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.0359
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    0.74
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.53
         upper limit
    1.03

    Secondary: Overall Response Rate (ORR) per RECIST1.1 as Assessed by Central Imaging Vendor

    Close Top of page
    End point title
    Overall Response Rate (ORR) per RECIST1.1 as Assessed by Central Imaging Vendor
    End point description
    ORR was defined as the percentage of the participants who experienced a Complete Response (CR; disappearance of all target lesions) or a Partial Response (PR; at least a 30% decrease in the sum of diameters of target lesions) and was assessed using RECIST 1.1 as assessed by the central imaging vendor. The percentage of participants who experienced a CR or PR was presented for the first course of study treatment per protocol. The analysis population included all randomized participants.
    End point type
    Secondary
    End point timeframe
    Up to approximately 59 months
    End point values
    Pembrolizumab Standard of Care (SOC)
    Number of subjects analysed
    153
    154
    Units: Percentage of Participants
        number (confidence interval 95%)
    45.1 (37.1 to 53.3)
    33.1 (25.8 to 41.1)
    Statistical analysis title
    Estimated difference in percentage
    Comparison groups
    Pembrolizumab v Standard of Care (SOC)
    Number of subjects included in analysis
    307
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.0159 [1]
    Method
    Miettinen & Nurminen method
    Parameter type
    Difference in percentage
    Point estimate
    12
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    1
         upper limit
    22.6
    Notes
    [1] - One-sided p-value based on Miettinen & Nurminen method.

    Secondary: Number of Participants Who Experienced an Adverse Event (AE)

    Close Top of page
    End point title
    Number of Participants Who Experienced an Adverse Event (AE)
    End point description
    An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who experienced at least one AE was presented for the first course study treatment per protocol. The analysis population included all randomized participants who received at least 1 dose of study treatment.
    End point type
    Secondary
    End point timeframe
    Up to approximately 59 months
    End point values
    Pembrolizumab Standard of Care (SOC)
    Number of subjects analysed
    153
    143
    Units: Participants
    149
    142
    No statistical analyses for this end point

    Secondary: Number of Participants Who Discontinued Study Treatment Due to an AE

    Close Top of page
    End point title
    Number of Participants Who Discontinued Study Treatment Due to an AE
    End point description
    An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who discontinued study treatment due to an AE was presented for the first course study treatment per protocol. The analysis population included all randomized participants who received at least 1 dose of study treatment.
    End point type
    Secondary
    End point timeframe
    Up to approximately 59 months
    End point values
    Pembrolizumab Standard of Care (SOC)
    Number of subjects analysed
    153
    143
    Units: Participants
    21
    20
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Up to approximately 91 months
    Adverse event reporting additional description
    All-cause mortality=all randomized participants (n=307) & adverse events (AEs)=participants who received ≥1 dose of study treatment. MedDRA terms neoplasm progression (NP), malignant NP, &disease progression unrelated to treatment were excluded. Per protocol, first & second course AEs were reported.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.0
    Reporting groups
    Reporting group title
    Pembrolizumab First Course
    Reporting group description
    Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years).

    Reporting group title
    SOC First Course
    Reporting group description
    Participants received 1 of 6 possible standard chemotherapy regimens: mFOLFOX6, or mFOLFOX6+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or mFOLFOX6+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle, or FOLFIRI, or FOLFIRI+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or FOLFIRI+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle.

    Reporting group title
    SOC Crossed over to Pembrolizumab
    Reporting group description
    Eligible participants with documented disease progression following chemotherapy in SOC arm switched over to receive pembrolizumab for up to 35 cycles (approximately 2 years).

    Reporting group title
    Pembrolizumab Second Course
    Reporting group description
    Participants who received pembrolizumab as a first course and stopped the first course of pembrolizumab due to complete response (CR) or completed the first course of pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator’s discretion for up to 17 cycles (approximately 1 year additional).

    Reporting group title
    SOC Crossed over to Pembrolizumab Second Course
    Reporting group description
    Participants who switched over from SOC and received pembrolizumab and subsequently stopped the first course of pembrolizumab due to complete response (CR) or completed the first course of pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator’s discretion for up to 17 cycles (approximately 1 year additional).

    Serious adverse events
    Pembrolizumab First Course SOC First Course SOC Crossed over to Pembrolizumab Pembrolizumab Second Course SOC Crossed over to Pembrolizumab Second Course
    Total subjects affected by serious adverse events
         subjects affected / exposed
    62 / 153 (40.52%)
    76 / 143 (53.15%)
    27 / 57 (47.37%)
    3 / 12 (25.00%)
    1 / 5 (20.00%)
         number of deaths (all causes)
    68
    58
    30
    4
    2
         number of deaths resulting from adverse events
    6
    7
    5
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Basal cell carcinoma
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bladder neoplasm
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Breast cancer
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Squamous cell carcinoma
         subjects affected / exposed
    2 / 153 (1.31%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    2 / 4
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rectal neoplasm
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oropharyngeal cancer
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Lung carcinoma cell type unspecified recurrent
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Infected neoplasm
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Colorectal adenoma
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cancer pain
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tumour associated fever
         subjects affected / exposed
    0 / 153 (0.00%)
    2 / 143 (1.40%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tumour pain
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vaginal neoplasm
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Aortic dissection
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Embolism
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Deep vein thrombosis
         subjects affected / exposed
    1 / 153 (0.65%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypertension
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Superior vena cava syndrome
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    0 / 153 (0.00%)
    3 / 143 (2.10%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    3 / 3
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Device related thrombosis
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Death
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Chest pain
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Asthenia
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gait disturbance
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General physical health deterioration
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mucosal inflammation
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    4 / 153 (2.61%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    2 / 4
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oedema peripheral
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Immune system disorders
    Hypersensitivity
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cytokine release syndrome
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Aspiration
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Chronic obstructive pulmonary disease
         subjects affected / exposed
    1 / 153 (0.65%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonitis
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Interstitial lung disease
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyperventilation
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dyspnoea
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    1 / 153 (0.65%)
    4 / 143 (2.80%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 4
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    Respiratory failure
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Psychiatric disorders
    Depression
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Confusional state
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Suicide attempt
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Investigations
    Liver function test increased
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neutrophil count decreased
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Norovirus test positive
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Accidental overdose
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hip fracture
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Head injury
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal stoma complication
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Stoma site haemorrhage
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract stoma complication
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tibia fracture
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Subdural haematoma
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Acute coronary syndrome
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute myocardial infarction
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Supraventricular tachycardia
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myocardial infarction
         subjects affected / exposed
    1 / 153 (0.65%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac arrest
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Angina pectoris
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Cerebrovascular accident
         subjects affected / exposed
    0 / 153 (0.00%)
    2 / 143 (1.40%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Occipital neuralgia
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Aphasia
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Carotid artery stenosis
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral infarction
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Amnesia
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Transient ischaemic attack
         subjects affected / exposed
    1 / 153 (0.65%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pseudobulbar palsy
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    1 / 153 (0.65%)
    2 / 143 (1.40%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Leukocytosis
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neutropenia
         subjects affected / exposed
    0 / 153 (0.00%)
    3 / 143 (2.10%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    3 / 3
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thrombocytopenia
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Febrile neutropenia
         subjects affected / exposed
    1 / 153 (0.65%)
    6 / 143 (4.20%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    5 / 6
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eye disorders
    Angle closure glaucoma
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vision blurred
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    7 / 153 (4.58%)
    2 / 143 (1.40%)
    2 / 57 (3.51%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 9
    1 / 2
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Constipation
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Anal fistula
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Colitis
         subjects affected / exposed
    3 / 153 (1.96%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    3 / 3
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Autoimmune colitis
         subjects affected / exposed
    2 / 153 (1.31%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal pain upper
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Enterocolitis
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Duodenal ulcer
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Duodenal perforation
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diverticular perforation
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diarrhoea haemorrhagic
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    4 / 153 (2.61%)
    9 / 143 (6.29%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    2 / 4
    9 / 9
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Faecaloma
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    1 / 153 (0.65%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastritis
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    2 / 153 (1.31%)
    2 / 143 (1.40%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Impaired gastric emptying
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ileus
         subjects affected / exposed
    1 / 153 (0.65%)
    3 / 143 (2.10%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 3
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal inflammation
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancreatitis
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intra-abdominal haemorrhage
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Large intestinal obstruction
         subjects affected / exposed
    1 / 153 (0.65%)
    2 / 143 (1.40%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Large intestine perforation
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intestinal perforation
         subjects affected / exposed
    0 / 153 (0.00%)
    2 / 143 (1.40%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    Upper gastrointestinal haemorrhage
         subjects affected / exposed
    1 / 153 (0.65%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Subileus
         subjects affected / exposed
    2 / 153 (1.31%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Small intestinal obstruction
         subjects affected / exposed
    2 / 153 (1.31%)
    5 / 143 (3.50%)
    3 / 57 (5.26%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 9
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Short-bowel syndrome
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    1 / 153 (0.65%)
    4 / 143 (2.80%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    2 / 4
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Autoimmune hepatitis
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Biliary dilatation
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute hepatic failure
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bile duct stenosis
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholestasis
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatic failure
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatitis
         subjects affected / exposed
    2 / 153 (1.31%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Immune-mediated hepatitis
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholangitis
         subjects affected / exposed
    0 / 153 (0.00%)
    2 / 143 (1.40%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Cholangitis acute
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Cholecystitis
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholecystitis acute
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Jaundice cholestatic
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Diabetic foot
         subjects affected / exposed
    1 / 153 (0.65%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rash
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin erosion
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin ulcer
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Glomerulonephritis
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute kidney injury
         subjects affected / exposed
    3 / 153 (1.96%)
    2 / 143 (1.40%)
    3 / 57 (5.26%)
    0 / 12 (0.00%)
    1 / 5 (20.00%)
         occurrences causally related to treatment / all
    2 / 3
    2 / 2
    0 / 3
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Autoimmune nephritis
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal impairment
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal failure
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Prerenal failure
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hydronephrosis
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Endocrine disorders
    Addison's disease
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Adrenocortical insufficiency acute
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Adrenal insufficiency
         subjects affected / exposed
    2 / 153 (1.31%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Autoimmune thyroiditis
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Pain in jaw
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myositis
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Back pain
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Autoimmune arthritis
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Arthralgia
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Clostridium difficile colitis
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cholecystitis infective
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    COVID-19
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal sepsis
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal infection
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Escherichia sepsis
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Escherichia pyelonephritis
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Endophthalmitis
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diverticulitis
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Device related infection
         subjects affected / exposed
    0 / 153 (0.00%)
    2 / 143 (1.40%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infection
         subjects affected / exposed
    2 / 153 (1.31%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Clostridium difficile infection
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Influenza
         subjects affected / exposed
    1 / 153 (0.65%)
    2 / 143 (1.40%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lower respiratory tract infection
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lymph gland infection
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Meningoencephalitis viral
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pelvic infection
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    3 / 153 (1.96%)
    2 / 143 (1.40%)
    2 / 57 (3.51%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    1 / 2
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia streptococcal
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyelonephritis
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyelonephritis acute
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Stoma site abscess
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory tract infection
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Stoma site infection
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urosepsis
         subjects affected / exposed
    0 / 153 (0.00%)
    2 / 143 (1.40%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular device infection
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Viral infection
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    0 / 153 (0.00%)
    3 / 143 (2.10%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    3 / 3
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypoglycaemia
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypoalbuminaemia
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyperglycaemia
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Failure to thrive
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dehydration
         subjects affected / exposed
    0 / 153 (0.00%)
    4 / 143 (2.80%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 7
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypokalaemia
         subjects affected / exposed
    0 / 153 (0.00%)
    2 / 143 (1.40%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypomagnesaemia
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Type 2 diabetes mellitus
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyponatraemia
         subjects affected / exposed
    1 / 153 (0.65%)
    1 / 143 (0.70%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 1
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Pembrolizumab First Course SOC First Course SOC Crossed over to Pembrolizumab Pembrolizumab Second Course SOC Crossed over to Pembrolizumab Second Course
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    145 / 153 (94.77%)
    142 / 143 (99.30%)
    53 / 57 (92.98%)
    11 / 12 (91.67%)
    4 / 5 (80.00%)
    Vascular disorders
    Hypertension
         subjects affected / exposed
    19 / 153 (12.42%)
    16 / 143 (11.19%)
    2 / 57 (3.51%)
    0 / 12 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    25
    23
    2
    0
    1
    Embolism
         subjects affected / exposed
    0 / 153 (0.00%)
    7 / 143 (4.90%)
    0 / 57 (0.00%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    0
    7
    0
    1
    0
    Hypotension
         subjects affected / exposed
    4 / 153 (2.61%)
    3 / 143 (2.10%)
    5 / 57 (8.77%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    4
    3
    5
    0
    0
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    19 / 153 (12.42%)
    30 / 143 (20.98%)
    5 / 57 (8.77%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    32
    57
    8
    1
    0
    Oedema peripheral
         subjects affected / exposed
    18 / 153 (11.76%)
    11 / 143 (7.69%)
    10 / 57 (17.54%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    24
    13
    11
    0
    0
    Mucosal inflammation
         subjects affected / exposed
    7 / 153 (4.58%)
    27 / 143 (18.88%)
    2 / 57 (3.51%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    7
    49
    2
    1
    0
    Malaise
         subjects affected / exposed
    10 / 153 (6.54%)
    6 / 143 (4.20%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    11
    8
    1
    0
    0
    Influenza like illness
         subjects affected / exposed
    14 / 153 (9.15%)
    4 / 143 (2.80%)
    3 / 57 (5.26%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    20
    4
    3
    0
    0
    Impaired healing
         subjects affected / exposed
    0 / 153 (0.00%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    0
    1
    0
    0
    1
    Fatigue
         subjects affected / exposed
    58 / 153 (37.91%)
    70 / 143 (48.95%)
    9 / 57 (15.79%)
    2 / 12 (16.67%)
    0 / 5 (0.00%)
         occurrences all number
    79
    176
    9
    3
    0
    Chills
         subjects affected / exposed
    4 / 153 (2.61%)
    7 / 143 (4.90%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    5
    9
    0
    0
    1
    Chest pain
         subjects affected / exposed
    8 / 153 (5.23%)
    3 / 143 (2.10%)
    4 / 57 (7.02%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    9
    4
    5
    0
    0
    Pain
         subjects affected / exposed
    4 / 153 (2.61%)
    3 / 143 (2.10%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    4
    3
    0
    0
    1
    Pyrexia
         subjects affected / exposed
    24 / 153 (15.69%)
    20 / 143 (13.99%)
    7 / 57 (12.28%)
    0 / 12 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    29
    28
    9
    0
    1
    Temperature intolerance
         subjects affected / exposed
    1 / 153 (0.65%)
    8 / 143 (5.59%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    2
    12
    0
    0
    0
    Peripheral swelling
         subjects affected / exposed
    4 / 153 (2.61%)
    0 / 143 (0.00%)
    3 / 57 (5.26%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    5
    0
    3
    0
    0
    Respiratory, thoracic and mediastinal disorders
    Rhinorrhoea
         subjects affected / exposed
    9 / 153 (5.88%)
    13 / 143 (9.09%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    10
    15
    1
    0
    0
    Productive cough
         subjects affected / exposed
    8 / 153 (5.23%)
    6 / 143 (4.20%)
    5 / 57 (8.77%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    8
    7
    6
    0
    0
    Oropharyngeal pain
         subjects affected / exposed
    4 / 153 (2.61%)
    8 / 143 (5.59%)
    3 / 57 (5.26%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    4
    8
    3
    0
    0
    Hiccups
         subjects affected / exposed
    2 / 153 (1.31%)
    8 / 143 (5.59%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    3
    10
    1
    0
    0
    Epistaxis
         subjects affected / exposed
    2 / 153 (1.31%)
    23 / 143 (16.08%)
    2 / 57 (3.51%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    3
    30
    2
    0
    0
    Dyspnoea
         subjects affected / exposed
    20 / 153 (13.07%)
    15 / 143 (10.49%)
    6 / 57 (10.53%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    25
    22
    8
    1
    0
    Dysphonia
         subjects affected / exposed
    2 / 153 (1.31%)
    8 / 143 (5.59%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    2
    9
    0
    0
    0
    Cough
         subjects affected / exposed
    26 / 153 (16.99%)
    23 / 143 (16.08%)
    7 / 57 (12.28%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    31
    26
    9
    1
    0
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    12 / 153 (7.84%)
    10 / 143 (6.99%)
    7 / 57 (12.28%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    14
    11
    7
    0
    0
    Discouragement
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    Depression
         subjects affected / exposed
    7 / 153 (4.58%)
    5 / 143 (3.50%)
    3 / 57 (5.26%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    7
    5
    3
    0
    0
    Anxiety
         subjects affected / exposed
    9 / 153 (5.88%)
    4 / 143 (2.80%)
    4 / 57 (7.02%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    11
    6
    4
    0
    0
    Anger
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    22 / 153 (14.38%)
    16 / 143 (11.19%)
    5 / 57 (8.77%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    33
    30
    6
    1
    0
    Aspartate aminotransferase increased
         subjects affected / exposed
    24 / 153 (15.69%)
    12 / 143 (8.39%)
    6 / 57 (10.53%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    33
    24
    6
    0
    0
    Blood alkaline phosphatase increased
         subjects affected / exposed
    22 / 153 (14.38%)
    6 / 143 (4.20%)
    2 / 57 (3.51%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    30
    9
    2
    0
    0
    Blood creatine phosphokinase increased
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    0
    0
    0
    0
    1
    Blood creatinine increased
         subjects affected / exposed
    7 / 153 (4.58%)
    4 / 143 (2.80%)
    2 / 57 (3.51%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    8
    5
    2
    1
    0
    Cardiac murmur
         subjects affected / exposed
    1 / 153 (0.65%)
    1 / 143 (0.70%)
    1 / 57 (1.75%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    1
    1
    1
    1
    0
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    8 / 153 (5.23%)
    3 / 143 (2.10%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    8
    5
    2
    0
    0
    Neutrophil count decreased
         subjects affected / exposed
    2 / 153 (1.31%)
    32 / 143 (22.38%)
    2 / 57 (3.51%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    2
    65
    10
    0
    0
    Platelet count decreased
         subjects affected / exposed
    2 / 153 (1.31%)
    10 / 143 (6.99%)
    2 / 57 (3.51%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    4
    29
    3
    0
    0
    Weight decreased
         subjects affected / exposed
    7 / 153 (4.58%)
    17 / 143 (11.89%)
    2 / 57 (3.51%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    7
    17
    2
    0
    0
    White blood cell count decreased
         subjects affected / exposed
    1 / 153 (0.65%)
    17 / 143 (11.89%)
    2 / 57 (3.51%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    48
    6
    0
    0
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    11 / 153 (7.19%)
    5 / 143 (3.50%)
    2 / 57 (3.51%)
    0 / 12 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    13
    5
    2
    0
    1
    Cardiac disorders
    Atrial fibrillation
         subjects affected / exposed
    3 / 153 (1.96%)
    2 / 143 (1.40%)
    0 / 57 (0.00%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    3
    2
    0
    1
    0
    Nervous system disorders
    Peripheral sensory neuropathy
         subjects affected / exposed
    3 / 153 (1.96%)
    31 / 143 (21.68%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    3
    51
    1
    0
    0
    Dizziness
         subjects affected / exposed
    24 / 153 (15.69%)
    27 / 143 (18.88%)
    6 / 57 (10.53%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    29
    54
    10
    1
    0
    Dysgeusia
         subjects affected / exposed
    5 / 153 (3.27%)
    13 / 143 (9.09%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    5
    14
    0
    0
    0
    Headache
         subjects affected / exposed
    21 / 153 (13.73%)
    22 / 143 (15.38%)
    17 / 57 (29.82%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    26
    37
    27
    0
    0
    Hemiparaesthesia
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    0
    0
    0
    0
    1
    Hypoaesthesia
         subjects affected / exposed
    2 / 153 (1.31%)
    5 / 143 (3.50%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    2
    7
    0
    0
    1
    Neuropathy peripheral
         subjects affected / exposed
    1 / 153 (0.65%)
    28 / 143 (19.58%)
    4 / 57 (7.02%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    41
    4
    0
    0
    Paraesthesia
         subjects affected / exposed
    6 / 153 (3.92%)
    8 / 143 (5.59%)
    1 / 57 (1.75%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    7
    10
    1
    1
    0
    Blood and lymphatic system disorders
    Thrombocytopenia
         subjects affected / exposed
    1 / 153 (0.65%)
    8 / 143 (5.59%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    1
    18
    0
    0
    1
    Anaemia
         subjects affected / exposed
    26 / 153 (16.99%)
    33 / 143 (23.08%)
    9 / 57 (15.79%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    32
    40
    18
    1
    0
    Leukopenia
         subjects affected / exposed
    0 / 153 (0.00%)
    3 / 143 (2.10%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    0
    12
    0
    0
    1
    Lymphadenopathy
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    0
    0
    1
    0
    1
    Neutropenia
         subjects affected / exposed
    3 / 153 (1.96%)
    27 / 143 (18.88%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    4
    52
    0
    0
    0
    Eye disorders
    Vision blurred
         subjects affected / exposed
    8 / 153 (5.23%)
    2 / 143 (1.40%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    8
    2
    1
    0
    0
    Ocular hyperaemia
         subjects affected / exposed
    5 / 153 (3.27%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    6
    0
    1
    0
    1
    Dry eye
         subjects affected / exposed
    9 / 153 (5.88%)
    3 / 143 (2.10%)
    0 / 57 (0.00%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    11
    4
    0
    2
    0
    Gastrointestinal disorders
    Abdominal pain upper
         subjects affected / exposed
    19 / 153 (12.42%)
    11 / 143 (7.69%)
    2 / 57 (3.51%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    21
    14
    3
    1
    0
    Ascites
         subjects affected / exposed
    1 / 153 (0.65%)
    3 / 143 (2.10%)
    3 / 57 (5.26%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    3
    3
    0
    0
    Constipation
         subjects affected / exposed
    26 / 153 (16.99%)
    45 / 143 (31.47%)
    13 / 57 (22.81%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    30
    76
    19
    0
    0
    Abdominal pain
         subjects affected / exposed
    34 / 153 (22.22%)
    41 / 143 (28.67%)
    8 / 57 (14.04%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    56
    62
    12
    0
    0
    Diarrhoea
         subjects affected / exposed
    65 / 153 (42.48%)
    89 / 143 (62.24%)
    17 / 57 (29.82%)
    2 / 12 (16.67%)
    0 / 5 (0.00%)
         occurrences all number
    107
    204
    36
    6
    0
    Vomiting
         subjects affected / exposed
    33 / 153 (21.57%)
    53 / 143 (37.06%)
    12 / 57 (21.05%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    53
    85
    20
    0
    0
    Stomatitis
         subjects affected / exposed
    10 / 153 (6.54%)
    43 / 143 (30.07%)
    4 / 57 (7.02%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    11
    75
    4
    0
    0
    Nausea
         subjects affected / exposed
    47 / 153 (30.72%)
    85 / 143 (59.44%)
    16 / 57 (28.07%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    69
    283
    23
    1
    0
    Haemorrhoids
         subjects affected / exposed
    2 / 153 (1.31%)
    10 / 143 (6.99%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    2
    10
    0
    0
    0
    Gastrooesophageal reflux disease
         subjects affected / exposed
    5 / 153 (3.27%)
    6 / 143 (4.20%)
    1 / 57 (1.75%)
    2 / 12 (16.67%)
    0 / 5 (0.00%)
         occurrences all number
    5
    8
    1
    2
    0
    Dyspepsia
         subjects affected / exposed
    9 / 153 (5.88%)
    16 / 143 (11.19%)
    5 / 57 (8.77%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    10
    21
    7
    0
    0
    Dry mouth
         subjects affected / exposed
    17 / 153 (11.11%)
    9 / 143 (6.29%)
    4 / 57 (7.02%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    18
    10
    5
    1
    0
    Skin and subcutaneous tissue disorders
    Alopecia
         subjects affected / exposed
    11 / 153 (7.19%)
    29 / 143 (20.28%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    11
    32
    0
    0
    0
    Dermatitis acneiform
         subjects affected / exposed
    3 / 153 (1.96%)
    8 / 143 (5.59%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    6
    22
    1
    0
    0
    Dry skin
         subjects affected / exposed
    19 / 153 (12.42%)
    14 / 143 (9.79%)
    9 / 57 (15.79%)
    3 / 12 (25.00%)
    1 / 5 (20.00%)
         occurrences all number
    21
    15
    11
    3
    1
    Superficial inflammatory dermatosis
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    Rash maculo-papular
         subjects affected / exposed
    8 / 153 (5.23%)
    3 / 143 (2.10%)
    2 / 57 (3.51%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    9
    3
    2
    0
    0
    Rash
         subjects affected / exposed
    19 / 153 (12.42%)
    16 / 143 (11.19%)
    10 / 57 (17.54%)
    2 / 12 (16.67%)
    1 / 5 (20.00%)
         occurrences all number
    27
    22
    12
    3
    1
    Psoriasis
         subjects affected / exposed
    4 / 153 (2.61%)
    0 / 143 (0.00%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    12
    0
    0
    0
    1
    Pruritus
         subjects affected / exposed
    25 / 153 (16.34%)
    12 / 143 (8.39%)
    15 / 57 (26.32%)
    0 / 12 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    37
    16
    24
    0
    1
    Palmar-plantar erythrodysaesthesia syndrome
         subjects affected / exposed
    1 / 153 (0.65%)
    25 / 143 (17.48%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    35
    1
    0
    0
    Skin hyperpigmentation
         subjects affected / exposed
    0 / 153 (0.00%)
    8 / 143 (5.59%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    0
    10
    2
    0
    0
    Renal and urinary disorders
    Proteinuria
         subjects affected / exposed
    5 / 153 (3.27%)
    11 / 143 (7.69%)
    2 / 57 (3.51%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    7
    28
    5
    1
    0
    Renal impairment
         subjects affected / exposed
    1 / 153 (0.65%)
    0 / 143 (0.00%)
    1 / 57 (1.75%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    1
    0
    1
    1
    0
    Endocrine disorders
    Hyperthyroidism
         subjects affected / exposed
    6 / 153 (3.92%)
    0 / 143 (0.00%)
    6 / 57 (10.53%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    6
    0
    6
    1
    0
    Hypothyroidism
         subjects affected / exposed
    19 / 153 (12.42%)
    4 / 143 (2.80%)
    7 / 57 (12.28%)
    2 / 12 (16.67%)
    0 / 5 (0.00%)
         occurrences all number
    20
    6
    7
    2
    0
    Musculoskeletal and connective tissue disorders
    Muscular weakness
         subjects affected / exposed
    5 / 153 (3.27%)
    1 / 143 (0.70%)
    3 / 57 (5.26%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    7
    1
    3
    1
    0
    Back pain
         subjects affected / exposed
    25 / 153 (16.34%)
    24 / 143 (16.78%)
    11 / 57 (19.30%)
    1 / 12 (8.33%)
    1 / 5 (20.00%)
         occurrences all number
    29
    27
    13
    1
    1
    Arthralgia
         subjects affected / exposed
    31 / 153 (20.26%)
    10 / 143 (6.99%)
    12 / 57 (21.05%)
    2 / 12 (16.67%)
    0 / 5 (0.00%)
         occurrences all number
    52
    11
    18
    2
    0
    Myalgia
         subjects affected / exposed
    8 / 153 (5.23%)
    12 / 143 (8.39%)
    3 / 57 (5.26%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    9
    15
    7
    0
    0
    Neck pain
         subjects affected / exposed
    4 / 153 (2.61%)
    5 / 143 (3.50%)
    1 / 57 (1.75%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    5
    5
    1
    1
    0
    Pain in extremity
         subjects affected / exposed
    18 / 153 (11.76%)
    11 / 143 (7.69%)
    6 / 57 (10.53%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    21
    11
    7
    1
    0
    Muscle spasms
         subjects affected / exposed
    8 / 153 (5.23%)
    5 / 143 (3.50%)
    3 / 57 (5.26%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    9
    7
    3
    0
    0
    Infections and infestations
    Candida infection
         subjects affected / exposed
    1 / 153 (0.65%)
    1 / 143 (0.70%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    1 / 5 (20.00%)
         occurrences all number
    1
    1
    0
    0
    1
    Cystitis
         subjects affected / exposed
    4 / 153 (2.61%)
    5 / 143 (3.50%)
    4 / 57 (7.02%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    4
    8
    6
    0
    0
    Urinary tract infection
         subjects affected / exposed
    14 / 153 (9.15%)
    15 / 143 (10.49%)
    7 / 57 (12.28%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    19
    23
    9
    0
    0
    Upper respiratory tract infection
         subjects affected / exposed
    16 / 153 (10.46%)
    8 / 143 (5.59%)
    2 / 57 (3.51%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    17
    11
    2
    0
    0
    Tooth infection
         subjects affected / exposed
    8 / 153 (5.23%)
    5 / 143 (3.50%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    9
    5
    1
    0
    0
    Paronychia
         subjects affected / exposed
    1 / 153 (0.65%)
    8 / 143 (5.59%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    1
    17
    0
    0
    0
    Oral candidiasis
         subjects affected / exposed
    3 / 153 (1.96%)
    6 / 143 (4.20%)
    4 / 57 (7.02%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    4
    6
    5
    0
    0
    Nasopharyngitis
         subjects affected / exposed
    20 / 153 (13.07%)
    10 / 143 (6.99%)
    8 / 57 (14.04%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    31
    13
    12
    0
    0
    Influenza
         subjects affected / exposed
    7 / 153 (4.58%)
    4 / 143 (2.80%)
    1 / 57 (1.75%)
    2 / 12 (16.67%)
    0 / 5 (0.00%)
         occurrences all number
    8
    4
    1
    2
    0
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    36 / 153 (23.53%)
    57 / 143 (39.86%)
    2 / 57 (3.51%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    49
    114
    2
    1
    0
    Dehydration
         subjects affected / exposed
    11 / 153 (7.19%)
    7 / 143 (4.90%)
    1 / 57 (1.75%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    11
    7
    1
    0
    0
    Hypercalcaemia
         subjects affected / exposed
    0 / 153 (0.00%)
    0 / 143 (0.00%)
    2 / 57 (3.51%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    0
    0
    2
    1
    0
    Hyperglycaemia
         subjects affected / exposed
    8 / 153 (5.23%)
    4 / 143 (2.80%)
    0 / 57 (0.00%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    24
    4
    0
    1
    0
    Hypoalbuminaemia
         subjects affected / exposed
    5 / 153 (3.27%)
    9 / 143 (6.29%)
    0 / 57 (0.00%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    5
    18
    0
    0
    0
    Hypokalaemia
         subjects affected / exposed
    13 / 153 (8.50%)
    23 / 143 (16.08%)
    2 / 57 (3.51%)
    0 / 12 (0.00%)
    0 / 5 (0.00%)
         occurrences all number
    25
    38
    4
    0
    0
    Hyponatraemia
         subjects affected / exposed
    10 / 153 (6.54%)
    6 / 143 (4.20%)
    3 / 57 (5.26%)
    1 / 12 (8.33%)
    0 / 5 (0.00%)
         occurrences all number
    11
    7
    4
    1
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    08 Dec 2017
    The major changes in the amendment 3 (AM3) included changing overall survival (OS) from a secondary outcome measure to the primary outcome measure, increasing sample size to 300 for interim analysis, changing the time of analyses to allow more data collection for progression-free survival (PFS) and OS outcome measures, allowing standard of care (SOC) participants to resume same therapy after surgery which they were on pre-operatively, allowing drug interruptions after sponsor consultation, and initiating tumor imaging for cross over and second course eligible participants on Cycle 1 Day 1.
    15 May 2018
    The major changes in the AM4 were to allow for a longer follow-up time, to reflect 35 pembrolizumab treatments in the crossover phase and to allow participants to move from the crossover phase to the second course treatment phase if criteria are met and that timing for final OS analysis was event driven.
    14 Jan 2020
    The major change of AM5 included changing the final analysis time for PFS and OS primary outcome measures.
    17 May 2021
    The major change of AM6 included updating the dose modification and toxicity management guidelines for immune-related adverse events (irAEs).
    25 Nov 2022
    The major changes of AM7 included change in the Sponsor entity name and allowing participants to enroll in the pembrolizumab extension study after study completion.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 21:12:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA